ClinicalTrials.gg
RecruitingNCT06976125Updated Jul 6, 2026

Application of a Prediction Model for Directing Antibiotic Use in the Treatment of Urinary Tract Infection in an Ambulatory Setting

An interventional study of Decision Aid-prediction model in Urinary Tract Infections, sponsored by University Hospitals Cleveland Medical Center. Recruiting at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-06.

Sponsored by University Hospitals Cleveland Medical Center · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
47
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 275 studies in Urinary Tract Infections with a site in United States — 44 open to participants now, 57 under way, 2 of them phase 3. Urinary Tract Infections · United States.

Planned enrollment
151st of 225
47 · median 100
Started
2026
with 18 others
No phase
94 of 275
19 open now
Primary completion
2026-12
later than 12 of 56 live
Registered
248th of 275
by date

Among the 275 studies in Urinary Tract Infections with a site in United States, this one is the 151st largest by planned enrollment of the 225 interventional ones that give a count, is one of 19 that started in 2026, is one of 94 with no phase, reaches primary completion later than 12 of the 56 other live ones, and was the 248th registered.

Urinary Tract Infections

808 studies on the registry are indexed under Urinary Tract Infections; 135 are open to participants now.

Browse Urinary Tract Infections studies →

Open to participants now

44 of the 275 studies in Urinary Tract Infections with a site in United States are open now. Recruiting first, the newest first:

38 more — sign in →

All 44 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 84 Urinary Tract Infections studies recruiting now, 51 (61%) set no upper age limit and 23 (27%) stop at 75 or younger; 17 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 275 studies in Urinary Tract Infections with a site in United States, or all of them as a file.
02

Study summary

Urinary tract infection (UTI) is when bacteria enter the urinary system and cause an infection. UTIs cause symptoms including burning when peeing, a feeling of an increased urge to pee, and cloudy or strong-smelling urine. Sometimes, severe UTIs can also cause fever, abdominal pain, and/or lower back pain.

In the emergency department (ED), healthcare providers rely on symptoms, along with a urine analysis and a urine culture to diagnose a UTI. A urine analysis involves taking a sample of urine and analyzing different factors like color, acidity, presence of blood cells, presence of bacteria. An abnormal urine analysis increases the likelihood that patients might have a UTI, but it does not confirm it. A positive urine analysis will lead to provider's sending a sample of urine for a urine culture. A urine culture is used to grow whatever bacteria is in the collected urine. If growth is seen on the culture, then this confirms a patient has a UTI. This also specifies which bacteria grew on the culture. The lab can also take it a step further and do an antibiotic test to check which antibiotic the bacteria is sensitive to.

When a urine analysis comes back abnormal in an ER setting, patients are prescribed an antibiotic before the culture and antibiotic sensitivity tests come back. If a patients condition is not critical, they will be discharged home before the culture results come back. If the culture comes back positive, the pharmacists will evaluate the culture and antibiotic sensitivity tests, then call patients to inform them whether they are taking a suitable antibiotic.

This study aims to decrease the unnecessary use of antibiotics because this contributes to antibiotic resistance which is considered a global public health issue. Antibiotic resistance occurs when bacteria develop the ability to withstand certain antibiotics that used to be effective against them, which makes it difficult to treat the infection. One of the factors that increase the risk of antibiotic resistance is the overuse of antibiotics.

In this study, investigators will be incorporating a prediction model and a negative callback system to decrease unnecessary antibiotic use.

03

Conditions studied

  • Urinary Tract Infections

Keywords

  • ER visits
  • Antibiotic use
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female sex
  • Age >18 years old
  • Discharged from the hospital after ER visit
  • Discharge ICD code consistent with a UTI diagnosis
  • Antibiotic prescribed for UTI at the time of discharge

Exclusion criteria

Exclusion Criteria:

  • Male sex
  • Necessity for chronic bladder catheterization or discharge with a urinary catheter
  • Patients who have an Emergency Severity Index (ESI) of 1 and 2
  • Patients who verbalize to the study team member that their pain is a 6 or higher
  • Patient set to be transferred to inpatient care
  • History of bladder augmentation
  • Pregnancy (this will be confirmed with a negative pregnancy test which is ordered in the ER)
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
47 participants (estimated)

Study arms

  • Experimental
    Presenting to ER for Urinary Tract Infection (UTI)

    Patients presenting to the a UH ER location for UTI symptoms.

    Device: Decision Aid-prediction model

Interventions

  • DeviceDecision Aid-prediction model

    ER physician will input the necessary de-identified data into the decision aid application. The decision aid determines if the patient has a high or low likelihood of having a positive urine culture. The patient with high likelihood of positive culture, will be prescribed empiric antibiotics per the UH guidelines for treating UTI in the ambulatory setting. Patients with a low likelihood of having a positive culture, will be discharged without antibiotics. Study team members will give the patient a handout describing what will happen in the event of a positive or negative culture. The culture call-back team, consisting of clinical pharmacists, will be notified.

06

What researchers measure

Primary outcomes

  1. Number of antibiotic free days as measured by medical record review.

    Time frame: Up to 2 weeks

Secondary outcomes

  1. Percentage of antibiotic prescriptions for patients discharged from the ER as measured by medical record review.

    Time frame: Up to 2 weeks

  2. Number of hospitalization since index ER visits as measured by medical record review.

    Time frame: Up to 2 weeks

  3. Number of ER readmission as measured by medical record review.

    Time frame: Up to 2 weeks

  4. Number of unscheduled primary care visits as measured by medical record review.

    Time frame: Up to 2 weeks

  5. Percent of false positive urinalysis as measured by discordance with culture obtained at time of ER visist

    Time frame: Baseline

  6. Percent of false negative urinalysis as measured by discordance with culture obtained at time of ER visist

    Time frame: Baseline

  7. Percentage of non-UTI associated urologic diagnoses as measured by medical record review

    Time frame: Up to 2 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Dec 2026, 9 months after the start.

Of 136 non-industry interventional studies with no phase under Urinary Tract Infections, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 39. This study's planned 9 months is below that.

Counting every sponsor, half of 154 studies reached it within 22 months; a quarter within 8 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
May 9, 2025
First posted
May 16, 2025
StartActual
Feb 20, 2026
Primary completionEst.
Dec 1, 2026
CompletionEst.
Dec 15, 2026
Last update
Jul 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06976125
Responsible party
David Sheyn (Physician, Case Western Reserve University) — Principal investigator
First posted
May 16, 2025
Start date
Feb 20, 2026
Primary completion
Dec 1, 2026 (estimated)
Completion
Dec 15, 2026 (estimated)
Last update
Jul 6, 2026

Study contacts

Jessica Abou Zeki
Contact
Jessica.AbouZeki@UHhospitals.org
216-286-0603
David Sheyn, MD
principal investigator · University Hospitals Cleveland Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion